Drug Trial Radar · NCT04504812
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,937
Actual
Start
Feb 1, 2021
Primary completion
Apr 8, 2025
Study completion Apr 8, 2025
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Pacira Pharmaceuticals, Inc
- First posted
- Aug 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.
Conditions
- Knee Osteoarthritis
Interventions
DuloxetineDrug
Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.
Intra-Articular InjectionCombination product
Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1 milliliter (mL) depo methylprednisolone (a steroid) and 2 mL 0.5% bupivacaine (an anesthetic) into the knee.
Nerve Procedure with long acting blocksProcedure
People assigned to receive this will have 1 milliliter (mL) of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.
Nerve Procedure with nerve ablationProcedure
People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.
Pain Coping Skills TrainingBehavioral
Participants will be provided with a written manual that includes login information for the pain coping skills training website. The participants will be expected to log into the system weekly, work through the modules, and participate in skills practice.
Best PracticesOther
Best Practices can include topical or oral nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen; physical therapy that may include aquatherapy; integrative treatments such as acupuncture, yoga, or a structured exercise program; and other non-invasive treatments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Pain Intensity as assessed by the Modified 4-item Brief Pain Inventory (BPI) Pain ScaleTime frame: Change from Baseline to 8 weeks post-randomization (mITT) and to 8 weeks post-treatment (per protocol) in Phase 1; Change from Baseline to 12 weeks post-randomization (mITT) and to 12 weeks post-treatment (per protocol) in Phase 2
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
University of California Davis
Sacramento, California
University of California San Diego
San Diego, California
VA Medical Center San Diego
San Diego, California
University of Colorado
Aurora, Colorado
University of Florida
Gainesville, Florida
Emory University
Atlanta, Georgia
Atlanta VA Medical Center
Decatur, Georgia
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Johns Hopkins
Baltimore, Maryland
Walter Reed Army Medical Center
Bethesda, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Weill Cornell University
New York, New York
University of Rochester Medical Center
Rochester, New York
University of North Carolina
Chapel Hill, North Carolina
Wake Forest University
Winston-Salem, North Carolina
Cleveland VA Medical Center
Cleveland, Ohio
University Hospitals
Cleveland, Ohio
Oregon Health and Science University
Portland, Oregon
Vanderbilt University
Nashville, Tennessee
University of Utah
Salt Lake City, Utah
University of Virginia
Charlottesville, Virginia
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.